Effect of telmisartan on levels of IL-1, TNF-α, down-regulated COX-2, MMP-2, MMP-9 and RANKL/RANK in an experimental periodontitis model

J Clin Periodontol. 2013 Dec;40(12):1104-11. doi: 10.1111/jcpe.12160. Epub 2013 Oct 10.

Abstract

Aim: The aim of this study was to evaluate the effect of telmisartan (TELM) on inflammation, oxidation and the expression of matrix metalloproteinases (MMPs) and the expression RANKL/RANK/OPG in the periodontal tissue of a rat model for ligature-induced periodontitis.

Materials and methods: Male Wistar albino rats were randomly divided into five groups of 10 rats each: (i) non-ligated, given water; (ii) ligated, given water; (iii) ligated, given 1 mg/kg TELM; (iv) ligated, given 5 mg/kg TELM; and (v) ligated, given 10 mg/kg TELM. All groups were treated with saline or TELM for 10 days. Periodontal tissue was analysed by histopathology; by the immunohistochemical examination of COX-2, MMP-2, MMP-9 and the RANKL/RANK/OPG pathway; and by ELISA analysis of the levels of IL-1β, IL-10, TNF-α, myeloperoxidase (MPO), malonaldehyde (MDA) and glutathione (GSH).

Results: Treatment with 10 mg/kg TELM resulted in reduced concentrations of MPO, MDA (p < 0.05) and the pro-inflammatory cytokine IL-1β (p < 0.05); reduced expression of MMP-2, MMP-9, RANK, RANKL and COX-2; and an increase in OPG. The levels of TNF-α were significantly reduced in all TELM-treated groups.

Conclusions: These findings confirm the involvement of TELM in reducing the inflammatory response, oxidative stress and bone loss in ligature-induced periodontitis in rats.

Keywords: anti-inflammatory; bone loss; periodontitis model; telmisartan.

Publication types

  • Comparative Study

MeSH terms

  • Alveolar Bone Loss / prevention & control
  • Animals
  • Anti-Inflammatory Agents / therapeutic use*
  • Antioxidants / therapeutic use
  • Benzimidazoles / therapeutic use*
  • Benzoates / therapeutic use*
  • Cyclooxygenase 2 / metabolism
  • Disease Models, Animal
  • Down-Regulation
  • Glutathione / metabolism
  • Interleukin-10 / analysis
  • Interleukin-1beta / metabolism
  • Male
  • Malondialdehyde / analysis
  • Matrix Metalloproteinase 2 / metabolism
  • Matrix Metalloproteinase 9 / metabolism
  • Osteoprotegerin / metabolism
  • Oxidative Stress / drug effects
  • Periodontitis / drug therapy*
  • Periodontitis / prevention & control
  • Peroxidase / metabolism
  • RANK Ligand / metabolism
  • Random Allocation
  • Rats
  • Rats, Wistar
  • Receptor Activator of Nuclear Factor-kappa B / metabolism
  • Telmisartan
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • Benzimidazoles
  • Benzoates
  • Interleukin-1beta
  • Osteoprotegerin
  • RANK Ligand
  • Receptor Activator of Nuclear Factor-kappa B
  • Tnfrsf11b protein, rat
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Malondialdehyde
  • Peroxidase
  • Cyclooxygenase 2
  • Ptgs2 protein, rat
  • Matrix Metalloproteinase 2
  • Mmp2 protein, rat
  • Matrix Metalloproteinase 9
  • Mmp9 protein, rat
  • Glutathione
  • Telmisartan